Radiopharmaceutical strategy & operations

Radiopharmaceutical programs need four kinds of expertise

Imaging, regulatory, clinical, and commercial.

Talk to our team See the evidence

Bracken brings all four, on a fractional or embedded basis, at any stage from first agent to commercial launch.

9 Senior consultants on radiopharmaceutical programs
400+ Peer-reviewed publications across the group
1st Radiopharmaceutical approval secured in Canada by an academic center
Seed to F500 Client scale, from startups to Fortune 500

What We Do

Bracken's radiopharmaceutical consulting plugs into programs wherever the needs lie: one advisor on an imaging endpoint, a fractional Head of Regulatory, or a group operating as your radiopharmaceutical team outright.

  • PET and SPECT agent development
  • Systemic Radiation Treatment and theranostics, alpha and beta emitters
  • Clinical trials with radiopharmaceuticals
  • Imaging endpoints, reading, analysis, and quantification
  • Regulatory strategy, FDA communications and meetings, INDs, NDAs, and CMC
  • Medical affairs, market access, and patient advocacy
  • Commercial due diligence, market validation, and competitive analysis
  • Commercialization strategy, market launch, and brand planning
  • Supply chain, logistics, and risk mitigation
  • Translational science and radiopharmaceutical laboratory support

Bracken is a concierge-style life sciences consultancy, and its consultants are regularly asked to serve as fractional CMOs, CSOs, CFOs, CCOs, COOs, or Heads of Regulatory. Programs that need an ongoing operating function rather than an advisor run through our Functional Service Provider model. Regulatory work sits alongside it under Regulatory Affairs.

See the Evidence

Our Consultants

C-suite radiopharma leaders, nuclear medicine physicians, and imaging biomarker experts. Full profiles and credentials.

Meet the Team

Our Publications

Peer-reviewed publications, book chapters, and patents from the consultants who would work on your program.

Browse Publications

Client Case Studies

Published engagements including radiopharmaceutical due diligence, imaging endpoint rescues, and regulatory readiness.

Case Study Library
FDA Meeting Request Calculator Get a complete response and meeting timeline for your FDA meeting request type.
Use the Calculator

Questions

What does radiopharmaceutical consulting cover at Bracken?
Clinical development strategy through commercialization, on diagnostic and therapeutic radiopharmaceuticals alike. That spans PET and SPECT agent development, clinical trials with diagnostic probes and imaging biomarkers, regulatory strategy, and market launch. Engagements run from a single advisor to a fully embedded team.
Can Bracken interface with the FDA on our behalf?
Yes. Bracken supports FDA communications and meetings, early IND strategy through NDA preparation, and CMC questions specific to radiopharmaceuticals, and has interfaced with the agency on behalf of client companies. US agent support is available for companies whose regulatory function sits outside the United States. See Regulatory Affairs for the wider capability.
Do you work on therapeutic radiopharmaceuticals as well as diagnostics?
Both. Diagnostic probes and imaging biomarkers on one side, and systemic radiation therapy and theranostics, including alpha and beta emitters, on the other. Several consultants have worked across the diagnostic and therapeutic sides of the same programs, including translational science and the management of radiopharmaceutical laboratories and byproducts.
Can you help with supply chain and market access?
Yes. Radiopharmaceutical supply chain, logistics, and risk mitigation are recurring pressure points given isotope half-lives and production capacity. Bracken also supports market access, commercial due diligence, market validation, and competitive analysis ahead of launch.
Radiopharma Roundtable

Where the conversations happen

Bracken roundtables convene developers, clinicians, and regulatory specialists on the questions the sector hasn't settled yet.

Radiopharma Roundtable Series

Talk to our team

Let's discuss where your radiopharmaceutical program is, and what's next.

Start a conversation